| Description | This product is a human neutralizing IgG that binds LASV GPC (glycoprotein precursor), termed 25.10C. The epitope involves residues essential for LAMP1 binding and also involve residues in the GP2 fusion loop. The antibody binds LASV GPC with high affinity and it has neutralizaing potency against LASV. This huamn antibody has been tested by Enzyme-linked immunosorbent assay, Bio-layer interferometry and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Lassa virus (LASV) |
| Cross Reactivity | wild-type LI, LI-R95M, and LIV |
| Epitope | Residues essential for LAMP1 binding and residues in the GP2 fusion loop |
| IC50 | 1.92 nM |
| Affinity | KD = 3.52 nM (wild-type LI) KD = 36.1±12.0 pM (LI-R95M) KD = 1.00±1.28 pM (LIV) |
| Isotype | Human IgG |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | Neutralization assay (Neut): Pretitrated amounts of ppVSV-LI-LASV (wild type or mutant) were incubated with the indicated concentrations of antibody at 37°C for 1 h before addition to confluent Vero monolayers in 96-well plates. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | LASV GPC |
| Alternative Name | Lassa virus glycoprotein precursor |
| Research Area | Infectious Disease |
| Related Disease | Lassa hemorrhagic fever |
